Third nerve palsy as the initial presenting sign of metastatic prostate cancer Navarro M, Ocaña A, Alañá M, Blanco O, Castro E, Fonseca E, Cruz JJ. American Journal of Clinical Oncology 31(4):407-8. FI: 2.206 (Q3) The Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease Cobaleda C, Cruz JJ, González-Sarmiento R, Sánchez-García I, Pérez-Losada J. Stem Cell Reviews 4(2):67-79. FI: 5.083 (Q1) New options in the treatment of locally advanced head and neck cancer: Role for induction chemotherapy Cruz JJ, Ocaña A, Navarro M, Barco ED, Fonseca E. Cancer Tratment Reviews 34(3):268-74. FI: 5.295 (Q1) Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer García-Mata J, García-Palomo A, Calvo L, Mel R, Cruz JJ, Ramos M. Clinical & Translational Oncology 10(11):739-44. FI: 1.146 (Q4) A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer Bayo-Calero JL, Mayordomo JI, Sánchez-Rovira P, Pérez-Carrión R, Illaramendi JJ, García-Bueno JM, González-Flores E, Crespo C, Ramos-Vázquez M, García-Palomo A, Ruiz-Borrego M, de la Haba J, Gómez-Bernal A, Yubero-Esteban A. Clinical Breast Cancer 8(3):264-8. FI: 2.065 (Q3) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, González S, López-Vega JM, GEICAM 9906 Study Investigators. Journal of the National Cancer Institute 100(11):805-14. FI: 14.069 (Q1) Spanish Society of Medical Oncology consensus on theuse of Erythropoietic stimulating agents in anaemic cancer patients Alberola V, Carrato A, Diaz-Rubio E, Gascón P, González M, Martín M, Alba E, Cassinello J, Colomer R, Cruz JJ, Barndas A, Camps C, Casas AM, Carulla J, Constenla M, Gavilá J, Isla MD, Massuti B, Provencio M, Rodríguez CA, Sanz J. Clinical & Translational Oncology 11: 717-736. FI: 1.146 (Q4) Non-pegylated liposomal doxorubicin (TLC-D99), paclitaxel and trastuzumab in her2 overexpressing breast cancer: a multicenter phase I/II study Cortes J, Di Cosimo S, Climent M, Cortés-Funes H, Lluch A, Gascon P, Mayordomo J, Gil J, Benavides M, Cirera L, Ojeda B, Rodríguez C, Trigo J, Vazquez J, Regueiro P, Dorado J, Baselga J. Clinical Cancer Research 15(1):307-14. FI: 6.747 (Q1) Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Lung Cancer 211-218. FI: 3.140 (Q1) , Sánchez-García I Castellanos A., Vicente-Dueñas C., Campos-Sánchez E., Cruz JJ., García-Criado FJ, García-Cenador MB, Lazo P, Pérez-Losada P. Cancer as a reprogramming-like disease: Implications in tumor development and treatmentSeminars in Cancer Biology 2010. FI: 6.918 (Q1)
|
